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The timely detection of metastatic infectious foci in gram-positive
bacteremia is crucial, because these foci often require prolonged
antibiotic treatment or drainage. The diagnosis of metastatic
infectious foci is difficult because localizing symptoms are often
absent. We investigated whether 18F-FDG PET/CT was able to
detect such foci and whether detection influenced clinical out-
come. Methods: One hundred fifteen nonneutropenic patients
with gram-positive bacteremia were prospectively included.
Patients with positive blood cultures growingStaphylococcus aur-
eus, Streptococcus species, or Enterococcus species were eligi-
ble when a risk factor for developingmetastatic infectious fociwas
present. 18F-FDGPET/CTwas performedwithin 2wkafter the first
positive blood culture. Abnormal 18F-FDG uptake had to be con-
firmed by radiologic, microbiologic, or pathologic studies. Results
were compared with a matched historical control group of 230
patients in whom no 18F-FDG PET/CT was performed. Results:
Significantly more patients were diagnosed with metastatic foci in
the study group (67.8% vs. 35.7%). Of the imaging investigations
performed, 18F-FDG PET/CT was the first to delineate infectious
foci in 35 patients (30%). In the remaining 70%, either symptoms
on physical examination or other imaging techniques first revealed
infectious foci. The sensitivity, specificity, negative predictive
value, and positive predictive value of 18F-FDG PET/CT were
100%, 87%, 100%, and 89%, respectively. Relapse rates
decreased from 7.4% to 2.6% among study patients (P 5 0.09)
and from8.9%to1.4%inpatientswithS.aureus (P50.04).Overall
mortality after 6 mo decreased from 32.2% to 19.1% in the 18F-
FDG PET/CT group (P 5 0.014). Conclusion: In the diagnostic
work-up of high-risk patients with gram-positive bacteremia, 18F-
FDG PET/CT is a valuable technique that results in lower mortality
rates. In patients with S. aureus bacteremia, relapse rates
decreased significantly after the addition of 18F-FDG PET/CT.
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The timely detection of metastatic infectious foci in
gram-positive bacteremia is crucial, because these foci re-
quire prolonged antibiotic treatment and, in some cases,
drainage. Insufficiently eradicated infectious foci result in
relapse of infection after cessation of antibiotic treatment in
12%–16% of patients (1,2). Mortality rates are significantly
higher in patients with metastatic complications or relapse
(3,4). The diagnosis of complicating infectious foci is often
difficult because up to 32% of these foci do not have any
localizing symptoms and signs (5,6). To date, no guidelines
addressing the diagnostic work-up of patients with gram-
positive bacteremia are available, except for the advice to
perform echocardiography in patients with Staphylococcus
aureus bacteremia (7).
A sensitive imaging technique suitable for screening of
complicating infectious foci might be helpful in identifying
patients in need of prolonged antibiotic treatment. CT,
MRI, and ultrasonography are less suitable as screening
methods when clues for specific sites of infection are absent
(8,9). 18F-FDG accumulates in metabolically active cells,
including activated leukocytes at the site of infection, en-
abling imaging of inflammatory processes (10). Therefore,
whole-body 18F-FDG PET/CT is potentially useful in delin-
eating metastatic infectious foci. In a retrospective study in
a selected patient population with bacteremia, 18F-FDG
PET/CT diagnosed, with a high negative predictive value,
clinically relevant new infectious complications in 45% of
patients (11). To date, there are limited data on infection
imaging by 18F-FDG PET/CT in deeply neutropenic pa-
tients. The present prospective study investigated whether
18F-FDG PET/CT enabled the early and accurate diagnosis
of metastatic infectious complications in patients with
gram-positive bacteremia and risk factors for complicating
infectious foci and whether the detection of metastatic foci
influenced clinical outcome by enabling early and more
accurate diagnosis of those foci.
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MATERIALS AND METHODS
Study Design and Patients
From November 2005 to January 2008, patients were prospec-
tively recruited from the Radboud University Nijmegen Medical
Centre, a 950-bed university hospital. All nonneutropenic (neu-
trophil count $ 0.5 · 109) adult patients (age, $18 y) were eli-
gible when at least 1 of the following known risk factors for the
presence of complicating infectious foci was present: community
acquisition, signs of infection more than 48 h before initiation of
appropriate treatment, fever more than 72 h after initiation of
appropriate treatment, and positive blood cultures more than 48
h after initiation of appropriate treatment (3,5,12). Patients primar-
ily admitted to the intensive care unit were included only when
transferred to regular patient wards within 14 d after the first
positive blood culture. Exclusion criteria were polymicrobial
infection and pregnancy. The records of all patients with positive
blood cultures growing S. aureus, Streptococcus species (exclud-
ing S. pneumoniae), or Enterococcus species were reviewed for
eligibility as soon as blood culture results were available. The
protocol was approved by the institutional review board. Written
informed consent was obtained from all patients. The study has
been registered in the ISRCTN database (no. 76425553).
A historical control group was defined using the electronic
database of the Department of Microbiology, in which all culture
results of clinical specimens are available. A pool of 456 patients
diagnosed with gram-positive bacteremia between January 2000
and December 2004 in whom 18F-FDG PET/CTwas not performed
was identified. Patients having at least 1 of the known risk factors for
developing complicating infectious foci were eligible for inclusion
in the control group. For every prospectively included patient, 2
control patients were matched for the type of microorganism, site
of acquisition of the infection, and the presence or absence of addi-
tional risk factors (treatment delay, persistent fever, or both).
Because blood cultures had not been obtained in a standardized
way in the retrospective cohort, the presence of persistently positive
blood cultures more than 48 h after the initiation of treatment was
not included as a risk factor in the matching strategy.
Clinical Features
The portal of entry was defined as a localized site of infection
preceding bacteremia. A central venous catheter was considered a
portal of entry if there was evidence of inflammation at the
insertion site or if culture of the catheter tip grew the same
microorganism as the blood culture in the absence of evidence for
another source of infection. Respiratory or urinary tract infections
were diagnosed as portals of entry only when specific symptoms
and signs were present in addition to positive culture results.
Phlebitis due to peripheral intravascular catheters and cellulitis,
categorized as skin infections, were considered portals of entry.
Bacteremia was considered to be nosocomial if only blood
cultures taken after more than 48 h of hospitalization were positive
and clinical signs of the infection were absent at the time of
admission. All other infections were considered community-
acquired. Both infectious foci without anatomic relation to the
portal of entry and direct extension of the infection beyond the
primary focus of infection were defined as complicating infectious
foci. Endocarditis was defined according to the Duke criteria (7).
Metastatic infectious foci not diagnosed during the first period
of infection, or a second period of bacteremia with the same
microorganism—either occurring within 3 mo of the first positive
blood culture—was defined as relapse of infection. Patients were
considered cured if no symptoms or signs of infection were present
at 3 mo after the discontinuation of antibiotic treatment. Infection
was considered contributory to death using the criteria described
elsewhere (12,13). The outcome was assessed in a masked fashion,
independent of the predicting variables and imaging results.
Diagnostic Work-up
18F-FDG PET/CT was performed as soon as possible after
inclusion. The maximum time between the first positive blood
culture and 18F-FDG PET/CT was 2 wk. Because antibiotic treat-
ment can be stopped after 2 wk in uncomplicated bacteremia, the
decision to prolong treatment because of infectious complications
should be made within those 14 d.
An integrated PET/CT scanner (Biograph; Siemens) was used
for data acquisition. Before 18F-FDG injection, patients fasted,
and glucose or insulin-containing intravenous infusions were dis-
continued for at least 6 h. In all diabetic patients at the time of 18F-
FDG injection, glucose was below 12.0 mmol/L. One hour after
intravenous injection of 200–220 MBq of 18F-FDG (Covidien), a
low-dose CT scan, without contrast enhancement, of the area
between the proximal femora and base of the skull was acquired
for anatomic correlation and attenuation correction of the PET
data. Subsequently, emission images of the same area were
acquired. 18F-FDG PET/CT images were evaluated by physicians
without knowledge of prior clinical evaluation and imaging
results. When 18F-FDG uptake was abnormal, conventional radio-
logic, microbiologic, or pathologic studies were performed when
possible, to confirm the diagnosis. All confirmed infectious foci
were reported to the attending physician.
Except for 18F-FDG PET/CT and the diagnostic procedures
needed for confirmation of abnormal 18F-FDG PET/CT results,
standard diagnostic and therapeutic procedures were followed.
Conventional radiologic techniques before 18F-FDG PET/CTwere
performed only at the discretion of the attending physician. Trans-
thoracic echocardiography, followed by transesophageal echocar-
diography, was to be performed in all patients. In the study group,
additional blood cultures were taken at 24, 48, and 72 h after the
first positive blood culture and 48 h thereafter when subsequent
blood cultures were positive. C-reactive protein and leukocyte
counts were ordered twice weekly. 18F-FDG PET/CT results were
considered abnormal if focal accumulation of 18F-FDG was
detected. Results were considered to be true-positive when abnor-
mal 18F-FDG uptake pointed to the organ or tissue in which infec-
tion was eventually diagnosed. Abnormal results were categorized
as false-positive when the abnormality could not be confirmed.
Normal test results were true-negative when no complicating infec-
tious foci were diagnosed within 2 wk after 18F-FDG PET/CT.
Abnormal test results not related to metastatic infection that were
caused by a confirmed alternative diagnosis (i.e., cancer) were also
considered true-negative. Antibiotic treatment was not influenced
by these foci. Normal test results were considered false-negative
when a localized infectious focus was diagnosed. Because of the
high physiologic 18F-FDG uptake within the brain, heart, and kid-
neys, 18F-FDG PET/CT was unsuitable for the detection of infec-
tious foci and was not evaluated for metastatic foci in these organs.
Within the study period (2000–2008), the diagnostic work-up or
treatment of patients with gram-positive bacteremia remained
unchanged in our hospital. If no complicating infectious foci were
detected, the standard duration of treatment was 14 d. Treatment
was prolonged to 6–12 wk in patients with complicating infectious
foci, depending on the site of infection and clinical response
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according to clinical practice. Endocarditis was treated according
to international guidelines (14).
Diagnosis and Patient Follow-up
The final diagnosis served as a standard of reference and was
based on microbiologic and pathologic results. If these results
were not available, the probable final diagnosis was based on
conventional radiologic procedures and clinical follow-up. The
final diagnosis was never based on the results of the 18F-FDG
PET/CT scan alone. Patient follow-up was performed for 6 mo
after the first positive blood culture. Epidemiologic data, number,
type, and results of all diagnostic tests and treatment data were
registered in a structured database (Access; Microsoft). Mortality
data were obtained for all patients at 3 and 6 mo after diagnosis.
Outcome Parameters
The primary outcome parameter was relapse of infection.
Secondary outcome measures were overall and attributable
mortality after 3 and 6 mo, duration of antibiotic treatment, and
number of diagnostic procedures performed to confirm 18F-FDG
PET/CT results.
Statistical Analysis
The study was designed to detect a statistically significant
difference of 10% between the study group and a historic control
group (a, 0.05; power, 0.80; 2-group x2 test, 2-sided). This design
required 115 evaluable study patients and 230 patients in the
historic control group. An intention-to-treat analysis was per-
formed. Differences between groups were tested with Fisher exact
tests for categoric variables. Differences were considered to be
statistically significant at a P value less than 0.05 (2-sided). Cox
proportional hazard models were used to analyze the relationship
between durations (survival, duration of therapy) and exploratory
variables after adjustment for potential confounding variables.
When no statistically significant confounding variables were
detected, Kaplan–Meier curves were estimated. We used SPSS
(version 16.0; SPSS, Inc.) for the analyses.
FIGURE 1. Enrollment of prospectively included study patients and historical control patients from database of Department of
Medical Microbiology. False-positive 18F-FDG PET/CT scan results were found in 7 patients. Localized colonic uptake, followed
by normal colonoscopy results, was seen in 2 patients. In 1 patient, shoulder uptake was not accompanied by hydrops on
ultrasound, but no puncture was performed. Confirmed mediastinal lymphadenopathy on CT was seen in 1 patient, but no
further diagnostic tests were performed. Lymphadenopathy had disappeared after 6 mo of follow-up. Pleural uptake without
pleural effusion on chest radiography was seen in 1 patient. She died before further investigations could be performed. In 1
patient, uptake in psoas was thought to be due to recent bleeding seen on CT. No cultures were taken in this patient, and she
was treated for 6 mo because of infected knee prosthesis. Abnormalities on CT disappeared. In 1 patient, 18F-FDG uptake was
present at site of pacemaker lead. He refused transesophageal echocardiography and was treated for 6 wk until presumed
infected kidney stone was removed. Infection did not recur.
1236 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 51 • No. 8 • August 2010
RESULTS
One hundred fifteen study patients and 230 control
patients were included in the study (Fig. 1). For 102 of
115 (89%) study patients, 2 perfectly matching controls were
found (Table 1). The remaining 13 study patients were
always matched with control patients with the same type
of microorganism. Overall, the control patients had fewer
additional risk factors than did the study patients (89% vs.
80%, P , 0.05). Treatment delay was added as a covariate
(confounder) in the final analysis but was insignificant in all
Cox proportional hazards models; therefore, Kaplan–Meier
analyses were performed. The identification of the portal of
entry of infection was similar for study and control patients.
18F-FDG PET/CT was performed in 111 of 115 study
patients at a median of 7 d (mean, 6.8 d) after the first blood
culture became positive. Significantly more metastatic foci
were identified in study patients than in control patients:
67.8% versus 35.7% (P , 0.05, Table 2). Compared with
27% of the controls, almost 40% of the study patients with
metastatic foci had more than 1 localization. More than half
of the patients with endocarditis in both groups also had
another metastatic localization. Figure 2 shows an example
of a CT-confirmed mycotic aneurysm that was asymptom-
atic. In 50% of all patients eventually diagnosed with
metastatic infection, no signs and symptoms suggesting
metastatic complications were present before 18F-FDG
PET/CT was performed. Of the imaging investigations per-
formed, 18F-FDG PET/CTwas the first to delineate 44 of all
124 (35%) metastatic infectious foci in 35 patients (30% of
all patients; in the remaining 70%, either symptoms on
physical examination or other imaging techniques first
revealed infectious foci). In 26 of these 35 patients, the
metastatic foci were not associated with clinical signs guid-
ing the attending physician. Nevertheless, in 7 of those
patients, prior investigations were performed (5 ultra-
sounds, 1 CT scan, and 1 MRI). In 5 of the 9 remaining
patients who did have guiding symptoms, prior diagnostic
procedures (4 CT scans and 1 MRI scan) had not revealed
the focus of infection. In the remaining 4 patients with
guiding symptoms, conventional diagnostic procedures
were delayed because of logistic reasons in 2 patients and
symptoms had not led to ordering additional imaging in the
remaining 2 patients. To confirm 18F-FDG PET/CT find-
ings, 24 ultrasounds, 16 CT scans, and 7 MRI scans were
obtained. Echocardiography was performed significantly
more often in the study group (83% vs. 29%, P 5 0.001).
The difference in patients with metastatic foci between both
groups remains significant (P , 0.001) when patients with
endocarditis alone are excluded from the analysis. For
delineating metastatic infectious foci, 18F-FDG PET/CT
had a sensitivity of 100%, specificity of 87%, negative
predictive value of 100%, and positive predictive value
of 89%. Information regarding the 7 patients with false-
positive 18F-FDG PET/CT results is shown in Figure 1.
The relapse rate was 7.4% in controls and 2.6% in the
study group (Table 3). In the S. aureus subgroup, however,
significantly fewer study patients had a relapse of infection
than controls (P 5 0.04). Overall mortality rate was 16.6%
in the study group at 3 mo of follow-up and 25.7% in the
control group (P 5 0.06). Eight patients had died after
relapse of infection in the control group versus 2 study
patients. The difference in overall mortality rate remained
significant during 6 mo of follow-up (19.1% in the study
group vs. 32.2% in the control group, P 5 0.014) in the
Kaplan–Meier models (Fig. 3). Infection contributed to
death in 80% of study patients and 74% of controls (P 5
0.7). After 6 mo of follow-up, infection-related mortality
decreased from 24.3% in controls to 14.8% in study
patients (P 5 0.049). In all but 2 patients in each group,
6-mo follow-up data were available. In the study group, the
TABLE 1. Baseline Characteristics of Study Patients and Historical Controls
Parameter Study patients (n 5 115) Controls (n 5 230) P
Male 56% 52% 0.57
Mean age 6 SD (y) 59 6 16 58 6 16
Matching criteria
S. aureus n 5 73 (64) n 5 146 (64) 1.0
Streptococcus species n 5 30 (26) n 5 60 (26) 1.0
Enterococcus species n 5 12 (10) n 5 24 (10) 1.0
Community acquisition 70% 68% 0.71
Additional risk factors
Treatment delay 27% 45% 0.01
Persistent fever 46% 37% 0.13
Remaining possible risk factors
Portal of entry unknown 52% 46% 0.30
Central venous catheter not removed within 48 h 5% 8% 0.50
Persistent positive blood cultures 16% 6%* 0.006
Immune suppression 22% 17% 0.30
*Not routinely obtained in control group.
Data presented in parentheses are percentages.
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median duration of treatment was longer. The median dura-
tion of treatment of patients without metastatic foci of
infection was 14 d in both groups (Fig. 4). When metastatic
infectious foci were present, study patients and controls
were treated significantly longer in both groups (median,
45 and 36 d, respectively). In the study group, 73 of 78
patients with metastatic foci were treated for more than 14
d. After the diagnosis of infectious complications, percuta-
neous or surgical drainage was performed in 30 of these
patients. Another 6 patients underwent cardiac valve
replacement. In 5 patients, treatment was not prolonged.
Three of those patients died. Six of the study patients were
still being treated at the end of follow-up.
DISCUSSION
This prospective study with matched historical controls
showed that relapse rate and mortality decreased when 18F-
FDG PET/CTwas performed in patients with gram-positive
bacteremia and at least 1 risk factor for developing compli-
cating infectious foci. Metastatic foci were found in a larger
proportion of study patients than in control patients (P ,
0.001) using 18F-FDG PET/CT. In previous studies inves-
tigating gram-positive bacteremia, the reported incidence of
complicating foci varies between 16% and 35%, which is
comparable to the percentage of complicating foci in the
control group (36%) (1,3,12,15). The percentage of com-
plicating infectious foci delineated in the 18F-FDG PET/CT
group, however, is much higher: 68%. In 35 patients (30%
of all patients), metastatic infectious foci were first revealed
by 18F-FDG PET/CT, despite the fact that 18F-FDG PET/
CT was considered experimental. Priority was given to
other clinically indicated diagnostic procedures, and 18F-
FDG PET/CT was sometimes postponed, as long as the
14-d time limit was not reached. The fact that 18F-FDG
PET/CT delineated significantly more endovascular, pul-
monary, and spinal infections in the study group than in
the controls, in whom no 18F-FDG PET/CT was performed,
is not surprising because these infections often lack local-
izing symptoms. These sites of infection, however, should
not be missed because treatment should be prolonged, and
surgical intervention is indicated in a proportion of these
patients. Remarkably, the duration of treatment in 6 of the
22 patients with endocarditis was dictated by a second
complicating infectious focus requiring prolongation of
FIGURE 2. 18F-FDG PET/CT of
patient with community-acquired
S. aureus bacteremia and proven
endocarditis, presenting with fever,
heart failure, and new cardiac murmur
(aortic valve insufficiency). 18F-FDG
PET/CT detected accumulation in left
common iliac artery (arrow) due to
clinically silent mycotic aneurysm. This finding resulted in prolonged treatment with antibiotics and monitoring of aneurysm
size. Coronal sections are shown for 18F-FDG PET (A), CT (B), and integrated 18F-FDG PET/CT (C).
TABLE 2. Localization of Metastatic Foci and Number of Foci First Detected by 18F-FDG PET/CT








Patients with foci identified 78 67.8 82 35.7 ,0.01
Total number of foci 124 113
Endocarditis 21 18.3 0 19 8.3 0.01
Endovascular 20 17.4 12 9 3.9 ,0.01
Lung 12 10.4 6 8 3.5 0.01
Liver 1 0.9 0 1 0.4 1.0
Spleen 1 0.9 1 0 0 1.0
Arthritis 10 8.7 3 28 12.2 0.37
Spondylodiskitis 11 9.6 8 10 4.3 0.09
Osteomyelitis 6 5.2 1 3 1.3 0.06
Psoas abscess 3 2.6 2 1 0.4 0.11
Soft tissue 11 9.6 4 12 5.2 0.18
Central nervous system 11 9.6 3* 7 3.0 0.02
Eye 3 2.6 0 0* 0 0.04
Joint prosthesis 9 7.8 3 5 2.2 0.02
Intraabdominal 4 3.5 1 6 2.6 0.74
Kidney 1 0.9 0 4 1.7 0.67
*Epidural extension of 18F-FDG uptake in 3 patients with spondylodiskitis, confirmed by MRI.
In 30 study patients and 22 controls, more than 1 metastatic localization was identified.
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antibiotic treatment. As expected, endocarditis was not
detected by 18F-FDG PET/CT because of physiologic
uptake in the myocardium (16). In line with international
guidelines, echocardiography was strongly advocated in our
protocol, as it was in clinical practice in previous years
(7,14). Nevertheless, echocardiography was performed sig-
nificantly more often in the study group, resulting in a more
frequent diagnosis of endocarditis. However, when patients
with endocarditis alone were excluded, metastatic foci were
still found significantly more often in the study group.
These findings indicate that the higher incidence of patients
with metastatic infections in the study group was not
caused by the increased use of echocardiography, because
significantly more metastatic infections at other anatomic
sites were also diagnosed.
The early detection of metastatic infectious foci facili-
tated the adaptation of treatment in patients at high risk of
relapse. In the study group, the overall relapse rate was only
2.6%. This did not differ significantly from the 7.4% among
controls. The study was designed to detect a 10% decrease
in relapse rate. In the subgroup with S. aureus bacteremia,
however, a significant improvement in relapse rate from
8.9% to 1.4% was found. Compared with other rates given
in the literature, our historic relapse rate in S. aureus bac-
teremia is low (8.9 vs. 12%–16%), possibly because of the
low number of methicillin-resistant S. aureus infections
(,2%) and concomitant vancomycin use in our study
(17). It was hypothesized that early mortality due to sepsis
could not be prevented by the early detection of metastatic
infection; thus, total mortality was regarded as only a sec-
ondary outcome parameter. However, overall and infection-
related mortality proved to be significantly lower in the
study group after follow-up of 6 mo.
A limitation of our study is the use of a historical control
group. However, the control group was both large and
matched for the risk profile for developing metastatic
infectious complications (3,5,12,18,19). Furthermore, the
study patients had more additional risk factors than the
control patients, taking into account the larger number of
persisting positive blood cultures. Thus, the overall risk for
relapse of infection should have been higher in the study
group. Because treatment delay might have been an impor-
tant confounder—being significantly more prevalent among
control patients—it was added as a covariate in the final
analysis. But adding treatment delay as a covariate did not
influence the outcome on survival at 6 mo of follow-up.
Because protocols for diagnostic evaluation and treatment
did not change within the period 2000–2008, there were no
differences in the management of patients with gram-pos-
itive infections. The median duration of treatment was sig-
nificantly longer in the presence of metastatic infectious
foci, with a difference between study and control patients.
This difference was probably due to the greater number of
endovascular infections (17% vs. 4%)—which require pro-
FIGURE 3. Kaplan–Meier curve for survival at 6-mo follow-
up in study and control groups.
TABLE 3. Clinical Endpoints at 3- and 6-Month Follow-up
Follow-up interval Study patients Controls P
3 mo
Total 115 230
Cure 72 (62.6) 151 (65.6) 0.63
Relapse 3 (2.6) 17 (7.4) 0.09
Persisting infection 21 (18.2) 3 (1.3) 0.001
Mortality 19 (16.6) 59 (25.7) 0.06
Relapse in S. aureus subgroup 1/73 (1.4) 13/146 (8.9) 0.04
6 mo*
Total 115 230
Cure 83 (72.2) 154 (66.9) 0.26
Persisting infection 8 (7) 0 ,0.001
Overall mortality 22 (19.1) 74 (32.2) 0.007
Infection-related mortality 17 (14.8) 56 (24.3) 0.049
Lost to follow-up 2 (1.7) 2 (0.9) 0.60
*At 6-mo follow-up, 8 patients had died after relapse of infection in control group vs. 2 in study group.
Data presented in parentheses are percentages. P values are estimated by Fisher exact tests.
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longed antibiotic treatment—that were found in the study
group. As stated, most of these infections were delineated
first by 18F-FDG PET/CT because of the lack of guiding
symptoms. Therefore, it is highly likely that the difference
in the number of metastatic foci and the reduced relapse
rate and mortality rates can be attributed to the addition of
18F-FDG PET/CT to the diagnostic regimen.
CONCLUSION
18F-FDG PET/CT detected clinically relevant new com-
plicating infectious foci in 30% of all study patients, with a
high negative predictive value. The addition of 18F-FDG
PET/CT to the diagnostic work-up led to a decrease of
relapse rates and overall and infection-related mortality of
gram-positive bacteremia by early detection and treatment
of metastatic infectious foci. 18F-FDG PET/CT is thus a
valuable technique in the diagnostic work-up of all patients
with gram-positive bacteremia and at least 1 risk factor for
developing metastatic complications.
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FIGURE 4 Kaplan–Meier curves for
duration of treatment. (A) Duration of
treatment between study and control
groups when metastatic foci were
present. (B) Duration of treatment
between study and control group when
metastatic foci were absent.
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